Beta Bionics (NASDAQ:BBNX) CFO Stephen Feider Sells 4,896 Shares

Beta Bionics, Inc. (NASDAQ:BBNX) CFO Stephen Feider sold 4,896 shares of the stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $17.03, for a total value of $83,378.88. Following the completion of the sale, the chief financial officer directly owned 165,931 shares of the company’s stock, valued at approximately $2,825,804.93. The trade was a 2.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Stephen Feider also recently made the following trade(s):

• On Friday, June 26th, Stephen Feider sold 5,104 shares of Beta Bionics stock. The stock was sold at an average price of $17.05, for a total value of $87,023.20.
• On Tuesday, June 2nd, Stephen Feider sold 6,676 shares of Beta Bionics stock. The stock was sold at an average price of $12.61, for a total value of $84,184.36.

Beta Bionics Stock Performance

Beta Bionics stock opened at $15.67 on Wednesday. The firm has a market cap of $698.26 million, a price-to-earnings ratio of -10.38 and a beta of 3.40. Beta Bionics, Inc. has a 52-week low of $8.80 and a 52-week high of $32.71. The firm has a 50 day moving average price of $12.28 and a two-hundred day moving average price of $15.31.

Beta Bionics (NASDAQ:BBNX) last posted its quarterly earnings data on Tuesday, April 21st. The company reported ($0.49) EPS for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.04. Beta Bionics had a negative net margin of 60.27% and a negative return on equity of 23.00%. The company had revenue of $27.63 million for the quarter. As a group, equities research analysts predict that Beta Bionics, Inc. will post -2.22 EPS for the current fiscal year.

Institutional Investors Weigh In On Beta Bionics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Strs Ohio bought a new stake in Beta Bionics during the 1st quarter worth approximately $29,000. EverSource Wealth Advisors LLC lifted its holdings in shares of Beta Bionics by 203.6% in the third quarter. EverSource Wealth Advisors LLC now owns 2,377 shares of the company’s stock valued at $47,000 after purchasing an additional 1,594 shares in the last quarter. Summit Securities Group LLC purchased a new position in shares of Beta Bionics during the fourth quarter valued at approximately $52,000. Legal & General Group Plc boosted its position in shares of Beta Bionics by 197.4% during the second quarter. Legal & General Group Plc now owns 3,976 shares of the company’s stock valued at $58,000 after buying an additional 2,639 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd lifted its stake in Beta Bionics by 1,075.7% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company’s stock valued at $61,000 after acquiring an additional 1,818 shares in the last quarter.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on BBNX shares. Wall Street Zen downgraded Beta Bionics from a “hold” rating to a “sell” rating in a research note on Sunday, March 29th. The Goldman Sachs Group dropped their price target on Beta Bionics from $19.00 to $17.00 and set a “buy” rating on the stock in a research note on Wednesday, May 27th. Leerink Partners cut their price target on Beta Bionics from $25.00 to $24.00 and set an “outperform” rating on the stock in a report on Wednesday, April 22nd. Weiss Ratings downgraded shares of Beta Bionics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, April 21st. Finally, Stifel Nicolaus lowered their price objective on shares of Beta Bionics from $22.00 to $20.00 and set a “buy” rating for the company in a research note on Wednesday, April 22nd. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $19.70.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual?hormone modes.